- 28 Jun 2018 Kymab and Roche clinical trial agreement for KY1044
- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
- 28 Mar 2018 Kymab statement on UK Court of Appeal’s decision
- 17 Jan 2018 Kymab VP Paul Kellam evidence to House of Lords
- 12 Jan 2018 Kymab ‘top European biotech to watch’ in 2018
- 4 Dec 2017 Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy
- 17 Nov 2017 Kymab makes UK Fast 50 for growth
- 8 Nov 2017 KY1044 strongly inhibits tumour growth in models
- 21 Sep 2017 KY1005 impressive in acute GVHD model
- 31 Jul 2017 Kymab's KY1005 antibody in clinical trial
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Kymab granted leave to appeal to the UK Supreme Court
Kymab has received permission to appeal the decision of the UK Court of Appeal to overturn the decision of the High Court trial judge, Mr...
Read article
Featured article: Forbes on Kymab: exciting the big guys
Forbes magazine recognises Kymab's work is 'exciting the big and little guys' and places the company in a select group of UK 'Unicorns'
Read article